215 related articles for article (PubMed ID: 24266818)
1. ERG protein expression as a biomarker of prostate cancer.
Falzarano SM; Magi-Galluzzi C
Biomark Med; 2013 Dec; 7(6):851-65. PubMed ID: 24266818
[TBL] [Abstract][Full Text] [Related]
2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
3. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
4. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.
Svensson MA; Perner S; Ohlson AL; Day JR; Groskopf J; Kirsten R; Sollie T; Helenius G; Andersson SO; Demichelis F; Andrén O; Rubin MA
Appl Immunohistochem Mol Morphol; 2014; 22(2):136-41. PubMed ID: 24517914
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia].
Allina DO; Kekeeva TV; Moskvina LV; Shikeeva AA; Andreeva YY; Zavalishina LE; Frank GA
Arkh Patol; 2015; 77(5):36-42. PubMed ID: 26978019
[TBL] [Abstract][Full Text] [Related]
14. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
[TBL] [Abstract][Full Text] [Related]
16. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
18. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Lorente JA; Fumado L; Serrano L; Serrano S; Lloreta J; Hernández S
Prostate; 2015 Aug; 75(11):1216-26. PubMed ID: 25939480
[TBL] [Abstract][Full Text] [Related]
19. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY
J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747
[TBL] [Abstract][Full Text] [Related]
20. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
